Bertis, a leader in proteomics-based precision medicine, has announced a strategic partnership with Singapore’s Innoquest Diagnostics to introduce advanced blood-based cancer detection technology across Southeast Asia. This collaboration aims to establish a robust infrastructure for early cancer detection, starting in Singapore and expanding to seven other countries, including Indonesia, Malaysia, and Thailand.
Bertis will supply its mass spectrometry-based proteomic analysis technology, which underpins its CHECK series of diagnostic tests, including the MASTOCHECK® for early breast cancer detection. Innoquest Diagnostics will manage the test operations and distribution within Singapore, leveraging its position as a subsidiary of Pathology Asia, a major network of independent laboratories in the region.
The partnership addresses a significant unmet need for early cancer detection in Southeast Asia, where high cancer incidence rates are coupled with low screening coverage. Blood-based diagnostics like MASTOCHECK® offer an accessible solution. Thomas Halusa, CEO of Innoquest Diagnostics, expressed enthusiasm for the collaboration, stating, “We are excited to partner with Bertis to bring innovative, blood-based cancer screening tools to Singapore and the broader region.”
Seung-man Han, CEO of Bertis, highlighted the strategic significance of the partnership, noting, “This partnership reflects the trust and executional experience we’ve built in Singapore around proteomics technologies.” The collaboration is set to expand through Pathology Asia’s network, enhancing the availability of advanced diagnostic solutions across Southeast Asia.
“`
